

### Amendments to the Claims

This following listing of the claims replaces all previous listings.

#### Listing of Claims

1. (Currently Amended) An immortalized isolated cell derived from luminal epithelial cells of a mammary gland, wherein said immortalized cell ~~which~~ is capable of proliferating and differentiating into cells of mammary gland luminal epithelial and myoepithelial cell lineages, and said immortalized isolated cell being capable of forming a cell culture comprising cells which are positive staining for the luminal epithelial marker ESA (ESA+) and negative staining for sialomucin (MUC-), so-called (ESA+/MUC-) cells.
2. (Currently Amended) ~~[[A]]~~The cell according to claim 1, which is isolated from suprabasal luminal epithelial cells of the mammary gland.
3. (Currently Amended) ~~[[A]]~~The cell according to claim 2, which is a human cell.
4. (Canceled)
5. (Previously Presented) A cell population composed of cells according to claim 1.
6. (Currently Amended) ~~[[An]]~~The immortalised cell line derived from the cell of claim 4.
7. (Currently Amended) ~~[[An]]~~The immortalised cell line according to claim 6, wherein the immortalising step comprises transfecting the cells with a nucleic acid molecule encoding an immortalising polypeptide.
8. (Currently Amended) ~~[[An]]~~The immortalised cell line according to claim 7, wherein the immortalising step comprises transfecting the cells with a nucleic acid molecule encoding a papillomavirus polypeptide selected from the group consisting of E6, E7 and a nucleic acid molecule comprising E6 and E7.

9. (Currently Amended) ~~[[An]]The~~ immortalised cell line according to claim 7, wherein the immortalising step comprises transforming the cells with at least one retroviral vector including an expression cassette comprising a nucleic acid molecule encoding a papillomavirus polypeptide selected from the group consisting of E6, E7 and a nucleic acid molecule comprising E6 and E7, and selecting the immortalised cells.

10. (Currently Amended) ~~[[An]]The~~ immortalised cell line according to claim 9, wherein the immortalising step is performed by transforming the cells with retrovirus-containing supernatant from the PA317 LXSHPV16E6E7 cell line and selecting the immortalised cells.

11. (Currently Amended) ~~[[An]]The~~ immortalised cell line according to claim 6 that in culture is capable of forming branching structures resembling terminal duct lobular units of the mammary gland in morphology and/or by marker expression.

12. (Currently Amended) ~~[[An]]The~~ immortalised cell line according to claim 6 which comprises cells that are positive staining for the keratin K19.

13. (Currently Amended) ~~[[An]]The~~ immortalised cell line according to claim 6 that is derived from a cell selected from the group consisting of a rodent cell, a porcine cell, a ruminant cell, a bovine cell, a caprine cell, a equine cell, a canine cell, a ovine cell, a feline cell and a primate cell.

14. (Cancelled)

15. (Original) ~~[[An]]The~~ immortalised cell line according to claim~~[[s]]~~ 13 that is a human cell line.

16. (Currently Amended) The immortalised cell line according to claim 6 which is deposited in accordance with the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at Deutsche Sammlung von

Mikroorganismen und Zellkulturen GmbH (DSMZ) on October 9, 2001 and has obtained the accession number DSM ACC 2529.

17. (Canceled)

18. (Currently Amended) A method ~~according to claim 17 in which the at least bi-potent cell is a cell according to an isolated cell for enrichment of a population of cells~~ derived from luminal epithelial cells of a mammary gland, the method comprising

a) obtaining a primary culture of cells from a biopsy of a mammary gland;

b) passing the cells from the primary culture through an anti-sialomucin column followed by retention of the flow-through in an anti-ESA column;

thereby obtaining an enriched population of cells which ~~[[is]]~~ are capable of proliferating and differentiating into cells of mammary gland luminal epithelial and myoepithelial cell lineages, ~~said isolated cell~~ cells being capable of forming a cell culture comprising cells which are positive staining for the luminal epithelial marker ESA (ESA+) and negative staining for sialomucin (MUC-), so-called (ESA+/MUC-) cells.

19.-31. (Cancelled).

32. (New) The method according to claim 18, wherein the enriched population of cells is isolated from suprabasal luminal epithelial cells of the mammary gland.

33. (New) The method according to claim 18, wherein the enriched population of cells is human.

34. (New) The method according to claim 18, additionally comprising immortalizing the enriched population of cells.

35. (New) The method according to claim 34, wherein the immortalising step comprises transfecting the cells with a nucleic acid molecule encoding an immortalising polypeptide.

36. (New) The method according to claim 34, wherein the immortalising step comprises transfecting the cells with a nucleic acid molecule encoding a papillomavirus polypeptide selected from the group consisting of E6, E7 and a nucleic acid molecule comprising E6 and E7; and selecting the immortalised cells.

37. (New) The method according to claim 34, wherein the immortalising step is performed by transforming the cells with retrovirus-containing supernatant from the PA317 LXS<sup>N</sup> HPV16E6E7 cell line and selecting the immortalised cells.

38. (New) An enriched cell population composed of cells according to claim 18.

39. (New) The immortalised cell line which is deposited in accordance with the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) on October 9, 2001 and has obtained the accession number DSM ACC 2529.